Real Time HCP Targeting: How Fast Should Pharma Act on Clinical Intent Signals?

Real-time HCP targeting is not just about receiving fresh data. It is about how quickly that data can change who a campaign reaches, what message is delivered and when the HCP sees it.

That distinction matters with clinical intent signals.

An HCP's clinical context can change between a diagnosis, a treatment decision, a prescription, an access issue and a fill. If the campaign responds after that context has changed, the signal may still be accurate, but the message may no longer be as relevant.

The challenge for pharma marketers is therefore not simply collecting more real-time data. It is reducing the time between clinical intent and campaign action.

What Real-Time HCP Targeting Actually Involves

A clinical signal must move through several stages before it becomes an ad impression:

Clinical activity → signal detection → HCP identification → audience activation → ad delivery
Each stage can cause delay.

Doceree's Clinical Intent Signals are designed to identify intent around the HCP's prescribing decision using signals from clinical and professional activity. Doceree's current technology positioning includes EHR activity, prescribing behaviour, point-of-care context and other decision-moment signals.

Detecting a clinical signal is only the first step. The signal still must be matched to the right HCP, activated within the campaign and delivered through the right channel.

For pharma teams, the real measure is the time between the clinical event and the first relevant exposure.

Where Latency Enters HCP Targeting

1. Signal detection

The first question is simple: when did the relevant clinical activity happen?

A platform may process information quickly after receiving it, but that does not automatically tell marketers how recent the original activity was.

This is why data freshness should be measured from the underlying event, not only from the latest platform update.

2. Verified HCP Identity

The clinical signal then needs to be connected to the right HCP.

Doceree combines Clinical Intent Signals with verified provider identity to support NPI-level targeting. This connects the clinical context with the physician the campaign is intended to reach.

Without accurate HCP identity, even a strong clinical signal has limited value for activation.

3. Signal-to-Activation

Once the HCP is identified, the signal needs to influence the campaign.

The audience and targeting rules must update so the HCP becomes eligible for the relevant message. Delays at this stage can reduce the value of a signal before activation even begins.

This is where clinical intent moves from insight to media action.

4. Activation-to-Exposure

Activation is complete only when the relevant message reaches the HCP.

Delivery depends on the channel, available inventory and campaign settings. The timing can therefore differ across point of care, programmatic, social and other HCP media channels.

For pharma marketers, the useful metric is therefore not just signal processing time.

It is signal-to-exposure time: how long it takes to move from the clinical signal to the first relevant HCP exposure

How Fast Should Pharma Act on Different Clinical Intent Signals?

Not every clinical signal needs the same response time.

Signals tied to prescribing, treatment changes or access may require faster activation, while research or educational activity can support longer follow-up.

The right timing depends on the signal, message and clinical context.

How Clinical Intent Signals Guide HCP Channel Activation

Clinical Intent Signals can inform HCP targeting across channels, but the timing should match the role of each channel.
Point of care can reach HCPs closer to the clinical workflow, while Programmatic, Social and CTV can extend engagement beyond that moment. Doceree’s Intent Powered HCP Suite applies Clinical Intent Signals across these channels to support more timely HCP engagement.

The goal is not to activate every channel at once. It is to reach the HCP through the right channel while the clinical signal is still relevant.

Measure Signal-to-Exposure Time in Real-Time HCP Targeting

Fresh clinical intent data loses value if HCP activation happens too late. By the time the message is delivered, the prescribing, treatment or access context may already have changed.

Pharma teams should track:

• Event-to-signal time: Time from clinical activity to signal availability.
• Signal-to-activation time: Time taken for the signal to influence HCP targeting.
• Activation-to-exposure time: Time from activation to the first relevant ad impression.
• On-time HCP reach: Percentage of eligible HCPs reached within the defined response window.

These metrics show whether real-time HCP targeting is responding quickly enough to the clinical context.

Clinical Intent Signals create more value when they reduce the gap between clinical activity, verified HCP identification and media activation.

 See how Clinical Intent Signals can support faster, more relevant HCP targeting across channels. 

Frequently asked questions